7 assets in Virus Associated Tumor

Therapeutic assets addressing Virus Associated Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Virus Associated Tumor	Institut Bergonié	P2	CCC (53)
Resiquimod Virus Associated Tumor	Institut Bergonié	P2	CCC (53)
Mdna11 Virus Associated Tumor	Medicenna Therapeutics, Inc.	P1/2	CCC (48)
Pembrolizumab Virus Associated Tumor	Medicenna Therapeutics, Inc.	P1/2	CCC (48)
Nivolumab Virus Associated Tumor	National Cancer Institute (NCI)	P1	CC (43)
Pomalidomide Virus Associated Tumor	National Cancer Institute (NCI)	P1	CC (43)
pds0101 Virus Associated Tumor	Weill Medical College of Cornell University	P2	NR ()